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Oxidized LDL in human carotid plaques is related to
symptomatic carotid disease and lesion instability
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Filis, MD, PhD,a Sophia Markantonis, BSc, PhD,c Efstathios K. Iliodromitis, MD, PhD,e
Vassilis G. Gorgoulis, MD, PhD,b and Ioanna Andreadou, BSc, PhD,d Athens, Greece
Background: Oxidative stress is an important determinant in atherosclerosis development. Various markers of oxidative
stress, such as oxidation of low-density lipoprotein (LDL), nitrosative stress, lipid peroxidation, and protein oxidation,
have been implicated in the initiation and/or progression of atherosclerosis, but their association with plaque erosion and
symptomatic carotid disease has not been fully defined. In addition, certain oxidative markers have been shown in various
models to promote plaque remodeling through matrix metalloproteinase (MMP) activation.
Objective: To perform a global investigation of various oxidative stress markers and assess for potential relationships with
destabilization and symptomatic development in human carotid plaques.
Methods: Thirty-six patients undergoing endarterectomy were evaluated and compared with 20 control specimens
obtained at the time of autopsy. Differences between stable and unstable plaques, symptomatic and asymptomatic
patients, and >90% and <90% stenosis were evaluated. Oxidized LDL (ox-LDL), nitrotyrosine (NT), malondialdehyde
(MDA), and protein carbonyls (PCs) levels were determined in atheromatic plaques homogenates by corresponding
biochemical assays. Immunohistochemical (IHC) analysis was also employed to determine the percentage and topological
distribution of cells expressing NT and metalloproteinase-9 (MMP-9) in serial sections from corresponding atheromatic
plaques. MMP-9 expression was further verified using Western blot analysis.
Results:Ox-LDL was increased in symptomatic patients (P < .05). Also, ox-LDL and NT levels were significantly higher
in unstable versus stable carotid plaques (P < .05, respectively). Furthermore, IHC serial section analysis, corroborated
by statistical analysis, showed a topological and expressional correlation between NT and MMP-9 (P < .05). MDA and
PCs levels, although increased in carotid plaques, did not distinguish stable from unstable carotid plaques as well as
symptomatic from asymptomatic patients with various degrees of stenosis.
Conclusion: All types of investigated oxidative stress markers were significantly increased in human carotid plaques, but
only ox-LDL levels were associated with clinical symptoms, while peroxynitrite products and MMP-9 were specifically
related to plaque instability. ( J Vasc Surg 2010;52:704-13.)
Clinical Relevance: Our results suggest that specific oxidative factors should be taken into consideration as additional
future potential markers that could be used to assist in prevention and therapeutic decision.Cardiovascular mortality is the major cause of death in
adults older than 65 years inWestern societies.1 Atheroscle-
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704rotic disease of the carotid artery is responsible for 20% to
30% of all strokes.2 At present, the only established crite-
rion for predicting stroke is the degree of carotid stenosis.3
It seems, however, that plaque instability is an essential
determinant of clinical manifestation of symptomatic ca-
rotid occlusive disease.4
The remodeling of a stable asymptomatic lesion into an
unstable, ruptured plaque is a complex process.5,6 A pleth-
ora of data5,7,8 have implicated a variety of factors in plaque
destabilization and eventually plaque rupture. Increasing
evidence has shown that inflammation has a crucial role in
the cascade of events related to plaque erosion.5,6 How-
ever, the molecular mechanisms that induce inflammation
and subsequent plaque instability have not yet been com-
pletely deciphered.
Available data have pointed to, among other mecha-
nisms, the oxidative stress in these processes.9 Oxidation of
low-density lipoprotein (LDL) has been shown to be a key
factor for the atherogenetic development.10,11 Various re-
active intermediates, derivatives of reactive oxygen (ROS)
and/or reactive nitrogen (RNS) species, are known to
mediate the oxidative modification of LDL.6,12,13 Among
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oxide (NO) and superoxide anion radicals,14 and malondi-
aldehyde, a product from lipid peroxidation,10 are powerful
LDL oxidants, which generate modified LDL with in-
creased atherogenic potential.10,11 Interestingly, oxidized-
LDL (ox-LDL) can lead to further production of ROS,
thus creating a sustained oxidative stress condition.6
Of note, activation of matrix metalloproteinases
(MMPs) has been shown to contribute also to plaque
destabilization, through extracellular matrix remodel-
ling.5,7 In certain cardiovascular experimental models,
this activation was nitrosative stress-intermediates depen-
dent,15-17 while in others, ox-LDL has been shown to be
responsible for their expression.18,19
Other forms of oxidative stress, such as lipid peroxida-
tion and protein oxidation, have been described in athero-
genesis,10,20 but their contribution in this process, and
specifically in symptomatic carotid disease and plaque insta-
bility generation, requires further investigation.
To the best of our knowledge, a global assessment of
various oxidative stress markers directly in human carotid
plaques stratified according to their histologic status, de-
gree of stenosis, and patients’ clinical status, is missing.
Therefore, in the present study, we first sought to collec-
tively determine the levels of various biochemical markers
related to oxidative stress in the same clinical setting of
human carotid plaques. These markers included ox-LDL,
along with nitrotyrosine (NT) - the fingerprint of peroxyni-
Table. Patients’ demographics and clinicopathological dat
Patients
Demographic data
Number
Mean age (range) 6
Male/female
Smoking
Current/past smokers
Clinical data
Hypertension
Diabetes
Hyperlipidemia
Ischemic heart disease
Aneurysm
Peripheral arterial occlusive disease
Clinical symptoms
Stroke
Transient ischemic attack
Amaurosis fugax
Angiographic carotic stenosis
90%
90%
Computed tomography brain (positive/negative)
Plaque histopathology status
Unstable
Stable
Medications
Statins
Angiotensin-converting enzyme inhibitors
-blockerstrite, malondialdehyde (MDA), and protein carbonyls(PCs), as indicators of nitrosative stress, lipid peroxidation,
and protein oxidation, respectively. Subsequently, we
looked into possible association of these markers with
expression of MMP-9 and plaque destabilization in human
carotid artery disease.
MATERIALS AND METHODS
Tissue collection
Patients. Between 2007 and 2009, carotid plaques
were prospectively collected from 36 random patients, who
had internal carotid artery stenosis 70% and underwent
carotid endarterectomy. Demographic data, clinicopatho-
logical data, medication, risk factors, and vascular comor-
bidities were recorded (Table). All patients were evaluated
preoperatively by a neurologist to be assigned as symptom-
atic and asymptomatic. Symptomatic patients were classi-
fied based on the presence of stroke, transient ischemic
attacks, and amaurosis fugax. They also underwent a cere-
bral CT scan for identification of brain infarcts. Arteriogra-
phy of the carotid bifurcation was performed in all patients
for this study. Degree of stenosis was determined according
to North American Symptomatic Carotid Endarterectomy
Trial (NASCET) criteria.3 Based on these measurements,
stenotic lesions were divided into two subgroups (70%-90%
and90%-99%), as previously described.21 The study pro-
tocol was approved by the Institutional Ethics Committee
erall Symptomatic Asymptomatic
36 19 17
(55-80) 67.2 66.9
/5 16/3 15/2
28 16 12
/16 9/7 5/7
31 15 16
10 5 5
18 10 8
20 10 10
3 2 1
11 7 4
19 19 —
6 6 —
9 9 —
4 4 —
16 7 9
20 11 0
/17 19/0 0/17
17 14 3
19 3 16
18 10 8
15 7 8
19 10 9a
Ov
7.05
31
12
19and all patients enrolled gave their informed consent.
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tained from autopsies served as control tissue samples for
the “baseline-expression” of the examined factors in human
arteries. Criteria for their selection included no previous
history of cardiovascular disease and cause of death unre-
lated to pathologic conditions (eg, accidents), and were
matched by gender (18 males and 2 women) and age
(mean, 65.8 years; range, 50-74 years) to the patients’
specimens under investigation.
Tissue preparation
All carotid plaque specimens were removed in the
operating room and were divided into two portions. One
portion was fixed immediately in 10% neutral-buffered
solution with 4% formaldehyde for 24 hours, and embed-
ded in paraffin. The second portion was immediately stored
at 70oC for further analysis of ox-LDL, MDA, NT, and
PCs and Western-blot analysis.
Histology
Hematoxylin and eosin staining was performed for
histological evaluation of the specimens. Two pathologists,
blinded to the clinical data, examined each specimen to
assess atheromatous plaque morphology, using the Ameri-
can Heart Association classification of atherosclerotic
plaques.22 According to this classification, carotid plaques
were assigned as fibroatherotic (type V) and complicated
(type VI). The latter type included plaques with intraplaque
hemorrhage, ulcer, or thrombus, which were considered
unstable.
Immunohistochemistry
Antibodies. For immunohistochemical analysis the
following antibodies were used: anti-Nitrotyrosine (HM11;
Zymed, Anti-Sel, Athens, Greece) at a 1:50 dilution,
MMP-9 sheep polyclonal antibody (SantaCruz Biogenesis,
Greece), in a 1:100 dilution. In serial sections, we also
determined the cellular phenotype of atherosclerotic
plaques. To identify macrophages/foam cells, smooth
muscle cells, and endothelial cells, the following mouse
monoclonal antibodies were used at a 1:50 dilution, respec-
tively: CD68 (KP1; Dako, Kalifronas, Greece), alpha-
smooth muscle actin (1A4; Dako), and CD34 mouse
(QBE nd/10; Biogenex, Aenorasis, Athens, Greece).7,23
Method. Immunohistochemistry was performed ac-
cording to the indirect streptavidin-biotin-peroxidase
method. In brief, 5 m paraffin sections were placed on
poly-L-lysine-coated slides, dewaxed, rehydrated, and in-
cubated for 30 minutes with hydrogen peroxide 0.3% to
quench the endogenous peroxidase activity. Unmasking of
the related proteins was carried out. The sections were
incubated with the primary antibody at 4°C overnight.
Biotin-conjugated secondary antibody was added at 1:200
dilution for 1 hour at room temperature (RT). The next
stage comprised 30 minutes incubation in StreptAB Com-
plex (1:100 stock biotin solution, 1:100 stock streptavidin-
hyperoxidase solution; Dako). For color development, we
used 3,3=-diaminobenzidine tetrahydrochloride (DAB,Sigma-Hellas, Athens, Greece) and hematoxylin as a
counterstain.
Evaluation. The staining pattern was considered pos-
itive only if cytoplasmic signal was discerned. Images were
obtained with a Zeiss-Axiolab microscope (Carl Zeiss
GmbH, Jena, Germany), employing a video analysis soft-
ware as previously described.8 The NT and MMP-9 label-
ing indices (LI) were determined as the percentage of cells
with cytoplasmic immunopositivity, irrespective of staining
intensity. Of note,MMP-9 extracellular matrix staining was
also observed and considered specific, but was not esti-
mated in terms of a LI. Two independent observers (AK
and VG) carried out slide examination. Inter-observer vari-
ability was minimal.
Immunoblotting
Protein extraction. Total protein extraction was per-
formed according to the protocol described elsewhere.7
Briefly, tissues were homogenized in 10 mM TrisHCl pH
8, 170 mM NaCl, 5 mM ethylenediaminetetraacetic acid,
0.5% nonidet P-40, 1 mM dithiothreitol and centrifuged at
1000  g at 4°C for 5 minutes. The supernatant was
collected and adjusted to 1g/mL protease and phospha-
tase inhibitors (Sigma-Hellas). Total protein concentration
was calculated using the Roti-Quant Bradford-Assay (Roth,
BioSure, Athens, Greece).
SDS-PAGE. Thirty g of protein from total extracts
of each sample were adjusted with NuPAGE LDS Sample
Buffer (Invitrogen, Anti-Sel, Athens, Greece) and loaded
on 4% to 12% gradient NuPAGE precast gels (Invitrogen).
Gel electrophoresis and transfer to polyvinylidene difluo-
ride membrane (Millipore, AlterChem, Athens, Greece)
were performed according to standard protocols. Blots
were blocked overnight in 2.5% gelatin solution in Tris-
buffered saline (Sigma-Hellas) at room temperature. Sub-
sequently, membranes were incubated for 3 hours with
primary antibody solution in Tris-buffered saline supple-
mented with 0.5% Tween-20 at RT, followed by a 45
minute incubation with HRP-conjugated anti-mouse sec-
ondary antibody (1:2500 dilution; R&D Systems, Anti-Sel,
Athens, Greece) at RT. Signal development was performed
with the Western Glo-Chemiluminescent Detection Sub-
strate (R&D Systems).7,23
Antibodies. The antibodies used were: anti-MMP-9
(1:500; sheep polyclonal, Neomarkers, BioAnalytica, Ath-
ens, Greece) and anti-tubulin (1:1000; AC-15, Abcam,
Anti-Sel, Athens, Greece) for assessing equal loading of
total protein and for normalizing the MMP-9 levels.
Ox-LDL determination
Ox-LDL was determined by enzyme-linked immu-
nosorbent assay (ELISA) according to the manufacturers’
instructions (Biomedica, Biomedica Gruppe, Vienna, Austria).
The detection limit of the assay was 0.8 ng/mL.
NT determination
NT, the fingerprint of peroxynitrite in the carotid
plaques, was determined by ELISA according to the man-
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Oxis Research, Beverly Hills, Calif). The detection limit of
the assay was 2 nM.
Measurement of carotid MDA
Human carotid samples were frozen at70oC until the
assay. On analysis, tissue samples were washed in ice-cold
NaCl 0.9%, blotted on absorbent paper, and weighed. Each
sample was minced in ice-cold 20 mM Tris-HCl buffer pH
7.4, in a 1:10 weight/volume ratio, and homogenized
using a Teflon pestle. After centrifugation at 3000  g for
10 minutes at 4oC, the supernatant was used for the bio-
chemical assay.24
MDA concentration was determined spectrophoto-
metrically at 586 nm and expressed in M (Oxford Bio-
medical Research Colorimetric Assay for lipid peroxida-
tion) with some modifications.23 The method used was
based on the reaction of the chromogenic reagentN-methyl-
2-phenylindole with MDA. One molecule of free MDA
combines with two molecules of the chromogenic agent to
produce a stable chromophore with a maximal absorbance
at 586 nm.
Briefly, 0.65 mL of 10.3 mM N-methyl-2-phenyl-
indole in acetonitrile was added to 0.2mL of tissue homog-
enate. After vortexing for 3 to 4 seconds and adding 0.15
mL of HCl 37%, samples were mixed well, closed with a
tight stopper, and incubated at 45o C for 60 minutes. The
samples were then cooled on ice, centrifuged, and the
absorbance was measured spectrophotometrically at 586
nm. A calibration curve, comprising accurately prepared
standard MDA solutions (from 2 to 20 nmol/mL), was
also run for quantitation. Measurements of each group
were performed in triplicate.
Determination of protein carbonyls content
A small amount of tissue was rinsed with phosphate-
buffer saline solution to remove red blood cells or clots. Tissue
was homogenized in 1 mL of cold phosphate-buffer pH 6.7,
containing 1mMEDTA, and then centrifuged at 10,000 g
for 15minutes at 4oC. The supernatant was removed, and the
tissue was stored at 80oC until use. A modification of the
technique of Levine et al,25 based on spectrophotometric
measurement of 2,4-dinitrophenylhydrazine (DNPH) deriv-
atives of protein carbonyls, was used to quantify protein-
carbonyl content. Briefly, 100 L of plasma was incubated
either with 500 L DNPH or 2 N HCl (blank) for 1 hour
at RT. The samples were then reprecipated with 600l 20%
trichloroacetic acid (TCA), incubated for 5 minutes on ice,
and subsequently extracted with ethanol:ethyl acetate (1:1,
volume/volume), three times at 11000 g for 10 minutes
at 4oC. The pellets were carefully drained and dissolved in 6
M guanidine solution in H2O. The difference spectrum of
the DNPH-treated sample versus the HCl control was
determined at 360 nm, and the results expressed as nmol
protein carbonyls/mg protein, using a molar extinction
coefficient of 22,000 M1 cm1.25 Protein concentration
was determined using the BioRad-Bradford assay.Data analysis and statistics
The clinical samples were stratified as predefined
groups of: 1) stable (noncomplicated) versus unstable
(complicated) plaques; 2) symptomatic versus asymptom-
atic lesions; 3) the presence of 90% versus 90% carotid
stenosis. Differences in the levels of ox-LDL, NT, MDA,
and PCs among all examined subgroups were estimated
with the unpaired t test with Welch correction or the
Mann-Whitney test/Kruskal-Wallis test (nonparametric
analysis of variance) for variables with significant differences
in their SDs, and their correlations were estimated by
Pearson coefficient or Spearman nonparametric coefficient.
The expressional relationship between the immunohisto-
chemically (IHC) assessed indices of NT and MMP-9,
within the predefined groups, were estimated by Pearson
coefficient or Spearman nonparametric coefficient. All cal-
culations were performed with the GraphPad Prism 4 soft-
ware (GraphPad Software Inc). Values of P  .05 were
considered statistically significant.
RESULTS
Increased ox-LDL levels in unstable and symptomatic
carotid plaques
We employed an ELISA assay to measure the ox-LDL
levels directly in homogenates of tissue carotids. Analysis in
our set of clinical samples showed a significant difference of
ox-LDL levels only in unstable plaques in relation to either
stable ones or the control group (P .05, respectively; Fig
1A). A similar significant increase in ox-LDL levels was also
found in symptomatic carotid lesions (P .05; Fig 1B), but
was not related to patients’ carotid stenosis (Fig 1C).
NT levels increase in a stepwise manner in relation to
plaque stability status
ELISA assessment in tissue homogenates. Similarly
as per ox-LDL, we assessed the NT status in the same tissue
homogenates in relation to plaque stability, carotid steno-
sis, and symptomatic disease. NT levels increased signifi-
cantly in a stepwise manner from the control group to the
stable one (P  .05), and finally to the unstable one (P 
.05; Fig 2A).
Although, no difference was found in the NT levels
regarding the status of the disease and of the carotid
stenosis (Fig 2B and 2C, respectively), NT was increased in
the patients stratified according to these parameters and
compared with control group (P .05, respectively; Fig 2B
and 2C, respectively).
Immunohistochemical analysis. Next we decided to
examine the type, the topological distribution, and the
percent of the cells expressing NT in the plaque, respec-
tively. The immunohistochemical expression of NT was
observed in the cytoplasm of vascular smooth muscle cells
(VSMCs) and inflammatory cells (macrophages and foam
cells) surrounding the lipid core (cap), as well as in the
shoulders of the plaque (Fig 3). NT IHC expression ranged
from 3% to 70% (average, 33.73% 23.0%) in the cohort of
patients.
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assessed levels (P  .05; data not shown).
MMP-9 expression correlates with NT in carotid
plaques
Data from cardiovascular models support that MMPs
can be activated by oxidative stress. Some have shown that
this activation is via intermediates of nitrosative stress,15-17
while others have shown an ox-LDL-dependence.18,19 To
investigate this issue in vivo, we examined MMP-9 expres-
sion and searched for potential relationships with NT and
ox-LDL, respectively, in our clinical setting. We choose
MMP-9 as a representative MMP to study, as we8 and
others26 have shown its significant increase in human rup-
tured carotid plaques.
MMP-9 IHC analysis. MMP-9 IHC analysis showed
its presence particularly in areas with intense inflammatory
infiltration (presence of macrophages and foam cells), in
VSMCs, and extracellular matrix (Fig 3). MMP-9 IHC
expression ranged from 2% to 70% (average, 32.06% 
23.30%) in the clinical samples. A higher MMP-9 IHC LI
was found in unstable plaques (35.26%  22.57%) com-
Fig 1. Oxidized LDL (ox-LDL) levels (ng/mL) in stable
(noncomplicated) and unstable (complicated) plaques (A); symp-
tomatic and asymptomatic lesions (B); 90% carotid stenosis and
90% carotid stenosis (C). *P .05 versus control samples, **P
.05 versus stable and asymptomatic.pared with stable ones (28.25%  24.32%).Interestingly, an IHC analysis in serial sections
showed that cells positive for NT immunohistochemical
staining were topologically localized in areas coinciding
with cells that exhibited MMP-9 IHC expression in both
stable and unstable plaques (Fig 3). Notably, the IHC
expression of these factors correlated (r 0.98, P .05;
Fig 4).
There was no association between MMP-9 expression
and ox-LDL levels.
Western blot analysis. In order to confirm that the
higher MMP-9 IHC LIs in unstable plaques correspond to
a quantitative increase in MMP-9 protein levels, we also
performedWestern blot analysis in representative randomly
selected stable and unstable samples. As shown in Fig 5,
MMP-9 expression levels were found significantly increased
in unstable plaques in comparison to the stable ones (P 
.05). Of note, both stable and unstable plaques also exhib-
ited higher MMP-9 protein levels than control plaques
Fig 2. Nitrotyrosine (NT) levels (nmol/mg protein) in stable
(noncomplicated) and unstable (complicated) plaques (A); symp-
tomatic and asymptomatic lesions (B); 90% carotid stenosis and
90% carotid stenosis (C). *P .05 versus control samples, **P
.05 versus stable plaques.(data not shown).
tures
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destabilization and symptomatic disease
Next, we extended our analysis to other markers of oxi-
dative stress involved in atherogenesis10,20 and investigated
for potential association(s) with plaque lesion destabilization.
MDA and PCs levels were significantly increased in the pa-
Fig 3. Immunohistochemical (IHC) analysis of matrix met
fromstable andunstable plaques.MMP-9 andNTIHCco-loc
magnification, respectively. Frames in 200magnification pictients’ cohort as compared with the control group (Figs 6 and7). Nevertheless, there was no significant difference in MDA
levels between stable and unstable plaques (P .05). A similar
resultwas also foundbetween symptomatic and asymptomatic
lesions (P  .05) as well as between patients with 90% and
90% carotid stenosis (P .05; Fig. 6).
Finally, no significant difference was found between levels
teinase-9 (MMP-9) and nitrotyrosine (NT) in serial sections
ion in stable (A) andunstable (B)plaques at 200 and400
represent the areas of 400magnification.allopro
alizatof PCs in stable and unstable plaques (P .05), symptomatic
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patients with 90% and 90% carotid stenosis (P  .05;
Fig. 7).
DISCUSSION
Atherogenesis is a complex process of multifactorial
etiology.5 Oxidative stress has been proposed as an impor-
tant determinant in this process acting directly as well as
Fig 4. Correlation between the immunohistochemical (IHC) la-
beling indices (LI) of matrix metalloproteinase-9 (MMP-9) and
nitrotyrosine (NT) in the examined cohort of human carotid plaques
(r 0.98, P .05).
Fig 5. Analysis of matrix metalloproteinase-9 (MMP-9) protein ex-
pression in stable and unstable plaques. Western blot analysis of
MMP-9 expression in representative samples of stable and unstable
plaques. (A); Histogram showing the significantly increased MMP-9
protein expression levels in unstable plaques, compared with stable
ones (P .05) (B).mediating the associated inflammation with this pathologiccondition.6,27 Nevertheless, a systematic assessment of var-
ious established oxidative stress markers, especially in rela-
tion to plaque destabilization and rupture, is, to the best of
our knowledge, missing. In this context, we performed a
global investigation of four establishedmarkers of oxidative
stress (such as ox-LDL, NT, MDA, and PCs) in a clinical
setting of human carotid plaques, stratified according to
their histologic status, degree of stenosis, and patients’
clinical status.
The first marker we assessed was oxidized-LDL. Oxi-
dation of LDL is known to participate in the initiation and
progression of atherogenesis.10,11 Nevertheless, direct as-
sessment of ox-LDL levels in tissue homogenates derived
from carotid plaques, and a systematic correlation with
classical clinicopathological parameters, such as plaque sta-
bility, carotid stenosis, and symptomatic disease, is scarce
and incomplete.28-30 In our study, a first important finding
we observed was the significantly increased ox-LDL levels
in carotid lesions of symptomatic patients. This result was
Fig 6. Malondialdehyde (MDA) levels (mol/mg protein) in
stable (noncomplicated) and unstable (complicated) plaques (A);
symptomatic and asymptomatic lesions (B);90% carotid stenosis
and 90% carotid stenosis (C). *P  .05 versus control samples.also corroborated by a corresponding increase in unstable
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an increase of plasma and plaque levels of ox-LDL in
patients with vulnerable carotid plaques,29 suggesting that
plasma ox-LDL assessment could be used as a potential
marker for symptomatology development. The vascular
wall ox-LDL has a crucial role in the development and
progression of atherosclerosis11; however, its role in the
mechanism of plaque instability and in the subsequent
clinical events remains poorly understood. Pathways that
oxidize lipids and proteins may thus be pivotal to the
atherosclerotic process. ROS and RNS species mediate the
oxidative modification of LDL.12 Oxidized LDL exerts
several biological effects that may contribute to the pro-
gression and the disruption of the atherosclerotic le-
sions.4,31 It is a chemoattractant for monocytes and T
lymphocytes, and it also inhibits macrophage mobility,
thereby promoting retention of macrophages into the arte-
rial wall.11 Oxidized LDL is cytotoxic and promotes endo-
thelial dysfunction and the evolution of the fatty streak into
a more advanced stage and unstable lesion.32 It can also
Fig 7. Protein carbonyls (PCs) levels (nmol/mg protein) in stable
(noncomplicated) and unstable (complicated) plaques (A); symp-
tomatic and asymptomatic lesions (B); 90% carotid stenosis and
90% carotid stenosis (C). *P  .05 versus control samples.accelerate atherogenesis by stimulating the expression ofseveral other genes into the arterial wall, such as interleu-
kin-1. In addition, ox-LDL can adversely affect coagulation
by stimulating tissue factor and plasminogen activator in-
hibitor-1 synthesis.33 Ox-LDL inhibits endothelium-
derived relaxation factor-mediated vasodilation.34 Over-
expression of oxidative LDL levels is an active stimulation
of the inflammation that occurs into the atherosclerotic
plaque, thus promoting the instability of the plaque and the
manifestation of clinical events. However, the identity and
the sources of the various oxidants that initiate and produce
LDL oxidation in artery carotid disease have not yet been
clearly defined.
Nitrosative stress may be a possible mechanism by
which plaque instability is promoted through ox-LDL pro-
duction.15,16 In this context, our results showing a signifi-
cant stepwise increase in NT levels specifically from stable
to unstable plaques are suggestive. The production of NO
by inducible nitric oxide synthase, in the presence of super-
oxide anion produced by macrophages, results in the for-
mation of peroxynitrite.14 Several lines of evidence indicate
that nitrotyrosine levels are not only detrimental for the
development of atherosclerosis,35-37 but are also linked
with oxidation of LDL.6,12,13 The absence of association
between ox-LDL and NT levels in our cohort of patients
implies that other mechanisms may also be responsible for
oxidation of LDL.
Of note, several cardiovascular models support that
MMPs can be activated by oxidative stress. Some have
shown that this activation is via intermediates of nitrosative
stress,15-17 while others support an ox-LDL-dependence.18,19
Our IHC analysis in serial sections showed a co-localization
of NT and MMP-9 that was also supported by a significant
statistical expressional correlation. The expression of
MMP-9 not only promotes the degradation of extracellular
matrix, but also induces the migration and proliferation of
smooth muscle cells.26,38 In association with endothelial
cell basement membrane degradation and enhanced endo-
thelial cell permeability, this results in greater influx of
plasma constituents including lipoproteins, thereby accel-
erating plaque formation and instability. In our study, we
showed a significant association between NT and MMP-9
expression for the first time in human carotid plaques,
suggesting that peroxynitrite probably decreases the integ-
rity of the connective network, leading to a decrease in
plaque stability and, therefore, facilitating plaque rupture.
Two other markers examined in this study are MDA
and PCs. MDA is a highly reactive dialdehyde and repre-
sents an alternative route of LDL oxidation,38,39 while
carbonyl groups (aldehydes and ketones) produced on
protein side chains after oxidation represent an established
marker of protein oxidation.40 In our study, we observed
significantly increased MDA and PCs levels in atheroscle-
rotic carotid plaques compared with normal lesions, but
there were no significant differences between the clinical
samples stratified according to the clinicopathologic pa-
rameters employed. Our data suggest that the lipid peroxi-
dation process, by increased MDA plaque production and
protein oxidation, probably contribute to plaque progres-
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associated with latter stages related to plaque vulnerability
and disruption.
In conclusion, our findings support that oxidative stress
is an important modulator of atherosclerosis. Specifically,
our observations point at ox-LDL and peroxynitrite as
important markers associated with advanced stages of this
disease, concerning plaque destabilization and rupture.
These findings could be exploited in the future in the form
of potential markers that could be used to assist in preven-
tion and therapeutic decision.
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